Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.
about
Nonmyeloablative allogeneic hematopoietic cell transplantationHow do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic MalignanciesChoice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow-Review of Published LiteratureHaploidentical Transplantation in Children with Acute Leukemia: The Unresolved IssuesHLA Haplotype Mismatch Transplants and Posttransplant CyclophosphamideMyeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant CyclophosphamideComparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched TransplantationModern approaches to HLA-haploidentical blood or marrow transplantationHaploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular TherapyReappraising the timing of transplant for indolent non-Hodgkin lymphomas.Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies.Might haplo "be the (better) match"?Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLAPost-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation.Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide.Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplantPlasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide.Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma.Recent developments in HLA-haploidentical transplantations.The evolution of T-cell depletion in haploidentical stem-cell transplantation.Advances in umbilical cord blood cell therapy: the present and the future.Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia.Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma.An exploration of the applicability of the refined disease risk index and its integration with other independent risk factors for individualized prognostication.Halfway there: the past, present and future of haploidentical transplantation.Allogeneic stem cell transplantation for sickle cell disease.Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia.Lower incidence of acute GVHD is associated with the rapid recovery of CD4+CD25+CD45RA+ regulatory T cells in patients who received haploidentical allografts from NIMA-mismatched donors: A retrospective (development) and prospective (validation) cohNonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies.Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients.Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.
P2860
Q26748780-17BC53E9-2FA9-443E-923F-8A66EF1F05D2Q26748867-68C4ED6B-C1D6-4C2A-8B2B-9802B91E0D68Q26749120-65F9224A-A6B7-49BD-9CCF-6C4482A0821EQ26749454-F4553A07-9149-4317-AF5B-67DFA1695777Q26750671-86331946-A9A5-4883-B487-DEDDAB49F702Q26752908-CF689C07-B571-4910-94BC-9D0CD38B9B48Q26767438-279F406E-F22D-4BFB-A2ED-C0C45746D9C4Q26771749-AC4ECF3D-7232-4D17-B6D8-686B918EC73BQ26797506-5793ADC4-D788-4A50-B0B4-F2B99AAF0D70Q28085397-7F4AE5BA-068E-4B29-9269-9AB0C6B5E045Q30248407-8B56E589-7EF6-4B54-83D3-2B7FDE910491Q30252339-AB0EAA92-66E1-4059-AA17-454108403387Q33868700-23166E1E-0DB0-4EDD-9AB5-CE2FCCE5BBD8Q36264895-8E520B36-1611-4564-A99C-914DFB7077AAQ36445665-A4F8CD67-E0EB-45B8-A161-8C7398D98462Q36596844-ED2E111B-956A-46D4-9909-197550077B02Q36596897-9414B6EE-5260-4AE3-BF81-BF0432747940Q36687119-6AEBE755-797B-4E3E-96C5-D0A3ECD1D9D9Q36724916-0F3C487B-E5B2-40ED-8F5E-67487C451CCAQ37012701-50BCB797-E8EC-4222-828C-CA431E279352Q37029856-1E04534E-16A2-4DAC-8400-13B5E2084D1AQ37317804-86EB8BB8-9813-4BE4-B69A-09AD7091D9A6Q37618838-44EE1F4A-8D35-4768-9278-191D031F3B57Q37618840-04F89FC7-0035-4123-BBC6-0A657CAF6F81Q38381708-4286A40A-799E-435E-993E-2919CB46E26FQ38619847-B6AE65B7-E677-4C34-B575-77959FAE335DQ38641733-0C2689E9-8729-4DAB-9D8A-3099CEFE30D5Q38673780-DD82EF54-EE76-47D7-9920-6C398BD10FE3Q38734758-40BD2BAD-D1C6-4509-8A8D-D4C092A3BF6DQ38743907-DB862C2F-3670-49F4-9B4D-0CDCE3032F39Q38777460-907EEAFE-FFC4-4A9F-97DD-B16F8AE140C7Q38802147-7543D7F9-9229-43DF-AD89-F20717B321CBQ38838264-B43B76F3-5A71-4A26-A7EE-4FD25A562CE5Q38920191-EB2BBBA7-43DE-4334-AF23-758DA4599A96Q38952815-29807348-4851-402B-9903-B5096B1CF0CFQ38970849-2E46318E-1B7F-423C-AFE2-125039726320Q39153244-FBE378EB-5599-4FE7-9568-053CC0E2BB81Q39232385-BC24BEDB-BFEC-40F1-B6EB-04E0D1545517Q40093716-16603226-C356-4F45-9D1F-8518BDDB150AQ40486613-FCC5EBFD-9C6E-482B-BAA0-4B61EA59EEF3
P2860
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Risk-stratified outcomes of no ...... nsplantation cyclophosphamide.
@ast
Risk-stratified outcomes of no ...... nsplantation cyclophosphamide.
@en
type
label
Risk-stratified outcomes of no ...... nsplantation cyclophosphamide.
@ast
Risk-stratified outcomes of no ...... nsplantation cyclophosphamide.
@en
prefLabel
Risk-stratified outcomes of no ...... nsplantation cyclophosphamide.
@ast
Risk-stratified outcomes of no ...... nsplantation cyclophosphamide.
@en
P2093
P2860
P1433
P1476
Risk-stratified outcomes of no ...... nsplantation cyclophosphamide.
@en
P2093
Amy E Dezern
B Douglas Smith
Carol Ann Huff
Christopher G Kanakry
Douglas E Gladstone
Ephraim J Fuchs
Gabrielle T Prince
Gary L Rosner
Heather J Symons
Hua-Ling Tsai
P2860
P304
P356
10.1182/BLOOD-2015-01-623991
P407
P50
P577
2015-03-26T00:00:00Z